DSP
Compliance Blueprint.
Forensic Node Active // Dubai
Statutory DNA Mapping // v1.0.26
The Sovereign Verdict
The Scientific Sovereign; High-Stakes R&D and IP Localization.
Strategic Overview
DSP is the UAE's premier hub for the life sciences. For 2026, the primary forensic challenge is the 'Modified Nexus Approach' (Action 5). For a pharma or biotech firm to claim 0% on royalties or patent income, they must prove the R&D wasn't just 'managed' here, but 'executed' here. This requires a granular link between laboratory bench-time, scientist payroll, and the resulting IP revenue.
I. Statutory Basis
Compliance Roadmap
- 01
R&D Statutory File: Implementing a project-based cost accounting system to track every dirham of localized research spend
- 02
Laboratory Asset Verification: Documenting the serial numbers and location of high-value lab equipment used in CIGA
- 03
Pharma Revenue Splitting: Forensically separating 'Trading/Distribution' (9%) from 'Patented Research' income (0%)
Audit Hotspots
Treating standard pharmaceutical distribution as 0% 'Qualifying' R&D income
Inadequate tracking of 'Contract Research' performed for foreign parent companies
Assuming laboratory 'Management' satisfies the physical 'Execution' requirement for IP Nexus
Sovereign Link Architecture
Jurisdictional Connectivity
15%
0%
9%
Qualifying Income requires physical CIGA within the zone boundaries. Article 18 mapping is mandatory to maintain 0% status.
Expert Consultation
Discuss your DSP structure with our senior forensic partners.